SLC5A2 and familial congenital mirror movements: Special emphasis is placed on the clinical evidence and application of various therapeutic agents, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RA), in the management of CMM.